
0.8459 Delayed Data As of Aug 12 | ![]() Today’s Change | 0.49 Today|||52-Week Range 1.61 | -16.25% Year-to-Date |
The 4 analysts offering 12-month price forecasts for Matinas BioPharma Holdings Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +254.65% increase from the last price of 0.85.
The current consensus among 4 polled investment analysts is to Buy stock in Matinas BioPharma Holdings Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.